Jintropin Original 10 МО Europharm is another variant of recombinant growth hormone that can be used as a doping agent in sports. Growth hormone (somatotropin) is responsible for the correct development and growth of the organism during childhood and adolescence, then its need decreases. If you start taking it, it will show its properties again and the tissues will start to grow, especially the muscles needed by sportsmen and women.
Main effects of Jintropin Original 10 МО Europharm
The most common area in sports for the use of Jintropin is bodybuilding. Somatropin does not increase strength and endurance, so it is not suitable for weightlifting, crossfit and similar areas. It is recommended where there is a need to form a beautiful and expressive figure, because growth hormone is able to:
- accelerate the entire muscle mass;
- prevent rapid muscle degradation;
- form a high quality relief;
- provide fat burning to problem areas.
In addition, somatotropin also affects the internal state of the body. It strengthens bone tissue, cartilage, joints and ligaments. Because of this, the risk of injury during training and other loads is significantly reduced.
Jintropin Original 10 МО Europharm also has a good effect on the skin, it has a rejuvenating effect. Both men and women can use it. The remedy has a small amount of side effects, they occur rarely and do not have serious consequences if the hormone is used correctly.
Possible negative effects
One of the common problems that occur when taking high doses of somatotropin is carpal tunnel syndrome. This is a situation where the nerve located in the wrist is pinched by the surrounding muscles or hard tissues, which start to grow due to the hormone.
- hyperglycaemia (high blood sugar);
- swelling due to excessive accumulation of fluid in the tissues;
- muscle pain.
The drug should not be used by pregnant women and during lactation. In sports fields, it is only used by athletes and adult athletes. In the presence of neoplasms or diseases with enlarged organs, somatotropin is contraindicated.
Rules of course construction
To achieve the effect, the drug should be taken 3-4 times a week. It is administered by injection at bedtime. The dosage is determined individually, based on:
- physical indicators of the athlete;
- the purpose of taking Somatotropin;
- individual sensitivity to the drug.
To understand the body’s response to the hormone, start with small doses and then gradually increase the amount.
To exclude contraindications and get more precise recommendations on the construction of a course, consult a doctor.
List of references
- Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LF, Lombardi G. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. European Journal of Endocrinology. 2008;159(6):389-397.
- Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(6):1587-1609.
- Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Hormone Research in Paediatrics. 2016;86(6):361-397.
- Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, Crowe BJ, Ross JL, Cassorla FG, Blum WF, Cutler GB Jr, Baron J. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Endocrinology & Metabolism. 2004;89(7):3140-3148.
- Saenger P, Attie KM, DiMartino-Nardi J; HGH Study Group. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. Journal of Clinical Endocrinology & Metabolism. 2007;92(8):2938-2945.